Healthy adults
Conditions
Interventions
Intake 2 capsules those contain test food 1 after dinner, for 12 weeks.
Intake 2 capsules those contain test food 2 after dinner, for 12 weeks.
Intake 2 capsules those contain no test food after dinne
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Males and females aged 50 to 79 when informed consent. 2) Subjects who aware that their memory ability reduced compare to own younger age. 3) Subjects giving written informed consent.
Exclusion criteria
Exclusion criteria: 1) Subjects who constantly use oral medicines, functional foods and/or supplements having a possibility of affecting test results. 2) Subjects who have previous and/or current medical history of serious disease such as cerebral infarction, cerebrovascular disease, psychosis, dementia and so on. 3) Subjects who are given continuous treatment by taking medicines. 4) Subjects who excessive alcohol intake. 5) Subjects who's MMSE-J scores are under 26 points. 6) Subjects who have already been done neuropsychological test at clinic. 7) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work. 8) Subjects who have previous medical history of drug and/or food allergy. 9) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. 10) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. 11) Males who donated over 400mL blood and/or blood components within the last three month to the current study. 12) Females who donated over 400mL blood and/or blood components within the last four month to the current study. 13) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. 14) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. 15) Others who have been determined ineligible by principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Basical 7 tests of the Cognitrax Plasmalogen Amyloid beta BDNF | — |
Secondary
| Measure | Time frame |
|---|---|
| High sensitive CRP in blood 8-OHdG in urine The incidence of side effects and adverse events. | — |
Countries
Japan
Contacts
Public ContactKazuyoshi Shibata
CPCC Company Limited Planning & Sales Department
Outcome results
None listed